Regorafenib-Induced Hand-Foot Skin Reaction in an Adolescent

被引：0

作者：

Murphy, Kiera ^{[1
]}

Patel, Bansri ^{[2
]}

Griffith, Shantelle ^{[2
]}

Helm, Thomas N. ^{[2
]}

机构：

[1] Penn State Coll Med, Hershey, PA 17033 USA

[2] Penn State Milton S Hershey Med Ctr, Dept Dermatol, Hershey, PA USA

来源：

PEDIATRIC DERMATOLOGY | 2025年

关键词：

adolescent; antineoplastic agents; hand-foot skin reaction; osteosarcoma; regorafenib; SORAFENIB; INHIBITORS; CANCER;

D O I：

10.1111/pde.15967

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Regorafenib is a multikinase inhibitor commonly used in the management of hepatocellular carcinoma, gastrointestinal stromal tumors (GIST), and colorectal cancer. It is also used off-label for progressive or metastatic osteosarcoma, which is the most common primary bone malignancy in children and adolescents. While hand-foot skin reaction (HFSR) is a well-documented side effect associated with regorafenib use, no standard guidelines currently exist for preventing and managing regorafenib-associated HFSR in children, or for HFSR and hand-foot syndrome related to other chemotherapy agents. We present a case of regorafenib-induced HFSR in an adolescent with metastatic osteosarcoma that highlights an effective dose-reduction regimen and treatment plan that ultimately resolved her grade 3 HFSR and allowed her to resume alternate anticancer treatment immediately.

引用

页数：4

共 23 条

[1]

[Anonymous], 2017, National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

[2] Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis [J].